SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is experiencing a significant sell-off following Anthropic's announcement about Claude Code's ability to automate COBOL modernization, which the community is debating as either a major disruption to IBM's legacy consulting revenues or an overblown market reaction given IBM's existing partnership with Anthropic and its own robust AI initiatives.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is seeing significant conversation after its earnings report delivered a revenue beat and robust 2026 guidance, sparking intense debate among investors. Many anticipate a substantial short squeeze given the high short interest and perceived undervaluation, while others remain cautious due to ongoing regulatory challenges and concerns about growth deceleration, leading to volatile price action.

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Vir Biotechnology Inc

Vir Biotechnology is trending following positive Phase 1 data for its prostate cancer drug and a significant collaboration with Astellas Pharma, sparking community discussions between those anticipating a major short squeeze and others cautioning that the stock historically struggles to sustain such sharp gains.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe is trending as a battleground stock caught in the broader software sector sell-off, with an intense community debate raging over whether AI will disrupt its core business or enhance its strong financial performance and deeply entrenched user base. Despite robust cash flow and aggressive share buybacks, the stock continues to face significant downward pressure from short interest and market skepticism.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

Crowdstrike is trending amid a sector-wide sell-off, as Anthropic's new AI security tool sparks market speculation about AI's potential to disrupt traditional cybersecurity. While some investors fear a re-valuation of the sector, many in the community believe these concerns are overblown and argue that AI actually increases the need for advanced cybersecurity defenses, viewing the dip as a buying opportunity.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending amid a heated bidding war for Warner Bros. Discovery, with Paramount submitting a higher offer and political pressures mounting from a DOJ antitrust probe and commentary from former President Trump. The community is actively debating whether Netflix should walk away from the deal to avoid overpaying, potentially triggering a stock rebound, as the uncertainty and prospect of a raised bid are currently weighing on its shares.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassian (TEAM) is trending amidst an intense sell-off driven by fears that rapidly advancing AI will disrupt its enterprise software offerings, leading to widespread community panic. This has ignited a fierce debate among investors questioning if the downturn is an irrational "SaaSpocalypse" or a justified revaluation despite strong earnings.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is dominating market conversation ahead of its crucial earnings report, fueled by analyst upgrades and expectations of continued AI-driven growth, while the community intensely debates if this will propel the stock to new highs or trigger a 'sell the news' event impacting broader indices.

FedEx Corp. is a holding company, which engages in the provision of transportation, e-commerce, business services, and business solutions. It operates through the following segments: FedEx Express, FedEx Freight, Corporate, Other, and Eliminations. The FedEx Express segment offers transportation and delivery services. The FedEx Freight segment refers to freight transportation services to business and residences. The FedEx Services segment includes sales, marketing, information technology, communications, customer service, technical support, billing and collection services, and certain back-office functions that support the company's operating segments. The Corporate, Other, and Eliminations segment is involved in the corporate headquarters costs for executive officers and certain legal and finance functions, as well as certain other costs and credits not attributed to the firm's core business. The company was founded by Frederick Wallace Smith on June 18, 1971, and is headquartered in Memphis, TN.

Fedex Corp

FedEx is trending amid intense community debate over its lawsuit seeking a full refund of past tariffs, with discussions split on corporate ethics and its broader implications. This contentious news is paired with the company's stronger-than-expected quarterly performance and ambitious long-term financial targets, alongside ongoing anticipation for its planned freight spin-off.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending as Paramount Skydance reportedly sweetens its all-cash offer for the entire company, including covering Netflix's breakup fee, fueling community debate on whether Netflix will match or exit given its own ongoing regulatory challenges.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting

Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting PR Newswire NEWYORK...

Are Medical Stocks Lagging  Actinium Pharmaceuticals (ATNM) This Year?

Here is how Actinium Pharmaceuticals (ATNM) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.

<ul class="summary-bullets"><li>The company’s latest research shows ATNM-400 achieving substantial tumor-growth suppression.</li><li>The therapy targets a validated antigen overexpressed in breast cancer and other solid tumors, such as Prostate Cancer and Non-Small Cell Lung Cancer.</li><li>Researchers observed that ATNM-400 induced irreversible DNA damage.</li></ul>Actinium Pharmaceuticals, Inc. (ATNM) stock was in the spotlight on Friday after the company announced promising new preclinical findings for its novel radiotherapy, ATNM-400, at the 2025 San Antonio Breast Cancer Symposium (SABCS).&nbsp;The Actinium-225 (Ac-225) antibody radioconjugate demonstrated strong anti-tumor activity across multiple breast cancer models, including hormone receptor–positive (HR+), triple-negative (TNBC), and treatment-resistant tumors.<h2 class="st-heading-2">ATNM-400’s Broad Potential</h2>The company’s latest research shows ATNM-400 achieving substantial tumor-growth suppression with minimal side effects in preclinical studies.&nbsp;The therapy targets a validated antigen overexpressed in breast cancer and other solid tumors, such as Prostate Cancer and Non-Small Cell Lung Cancer (NSCLC), positioning ATNM-400 as a potential pan-tumor radiotherapy solution.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/ATNM">Actinium’s stock</a> traded over 3% higher in Friday’s premarket. On Stocktwits, retail sentiment around the stock remained in ‘neutral’ territory amid ‘normal’ message volume levels.&nbsp;<h2 class="st-heading-2">Effectiveness Against Resistant Cancer Types</h2>ATNM-400 displayed potent cytotoxic effects in models resistant to standard-of-care treatments, including trastuzumab-resistant BT474-Clone5 and tamoxifen-resistant MCF7-Tam1 cells. Combining ATNM-400 with conventional therapies like trastuzumab or tamoxifen enhanced tumor regression in preclinical models."Patients whose tumors progress after endocrine therapy or HER2-targeted therapies face limited and often toxic treatment options. The data presented at SABCS show that ATNM-400 generates potent, targeted DNA damage even in highly resistant breast cancer models, while maintaining a favorable tolerability profile,” said&nbsp;Aditya Bardia, Program Director, Breast Medical Oncology at Geffen School of Medicine, University of California, Los Angeles.Researchers observed that ATNM-400 induced irreversible DNA damage, marked by elevated phosphorylation of H2AX (pH2AX) and AKT (pAKT), consistent with alpha-particle–driven double-strand DNA breaks.&nbsp;ATNM stock has gained over 17% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvidia-weighs-boosting-h200-ai-chip-production-report/cLICS1gREF8">Nvidia Weighs Boosting H200 AI Chip Production: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Actinium Pharmaceuticals, Inc. logo is displayed on the screen of a tablet. 

Why Is Actinium Pharmaceuticals Stock Rising Today? 

The Actinium-225 (Ac-225) antibody radioconjugate demonstrated strong anti-tumor activity across multiple breast cancer models.

Equity

The Actinium-225 (Ac-225) antibody radioconjugate demonstrated strong anti-tumor activity across multiple breast cancer models.


Are Medical Stocks Lagging  Alpha Cognition Inc. (ACOG) This Year?

Here is how Alpha Cognition Inc. (ACOG) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.

Is Alpha Cognition Inc. (ACOG) Stock Outpacing Its Medical Peers This Year?

Is Armata Pharmaceuticals (ARMP) Stock Outpacing Its Medical Peers This Year?

Here is how Armata Pharmaceuticals, Inc. (ARMP) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.

Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year?

Here is how Actinium Pharmaceuticals (ATNM) and Avadel (AVDL) have performed compared to their sector so far this year.

Regencell Bioscience Holdings Ltd (3,500% Jump in Message Volume)Hong Kong-based Regencell focuses on traditional Chinese medicine for neurocognitive disorders, particularly ADHD and autism. Reports suggest its recent rally was fueled by insider buying, with insiders owning 81% of the company.&nbsp;However, a Stocktwits&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rgc-stock-more-than-triples-this-year/ch7KEpeRbcl">poll</a> indicates retail traders remain skeptical, with some flagging it as a potential pump-and-dump risk.&nbsp;The stock has surged 1,054% this year.GlucoTrack Inc. (2,800% Jump in Message Volume)GlucoTrack develops non-invasive glucose monitoring devices. It announced that safety and performance data from its first-in-human trial of a long-term continuous blood glucose monitoring (CBGM) system will be presented at the 2025 ATTD conference.&nbsp;CEO Paul V. Goode highlighted its potential for real-time glucose monitoring without on-body wearables, calling it a transformative step in diabetes management.&nbsp;GlucoTrack stock is down over 96% year-to-date (YTD).TC Biopharm (Holdings) Plc (1,300% Jump in Message Volume)TC Biopharm&nbsp;<a href="https://stocktwits.com/symbol/TCBP">received</a> a Nasdaq delisting notice due to its share price falling below $1. Trading will be suspended on Monday, with its American depository shares expected to move to OTC Markets.&nbsp;The company is also shifting to a contract development and manufacturing organization (CDMO) model, cutting about 50% of its workforce to reduce operational burn by 55%. This is projected to save $2.1 million in 2025 and $4.2 million annually.&nbsp;The stock is down over 95% YTD.AbbVie Inc. (700% Jump in Message Volume)Erste Group upgraded AbbVie to ‘Buy’ from ‘Hold’, according to The Fly, citing strong sales growth projections through 2029, supported by upcoming product launches. The research firm expects earnings per share (EPS) to rise significantly in 2025, ranging from $12.12 to $12.32.&nbsp;AbbVie recently agreed to acquire a next-gen obesity drug from Denmark-based Gubra A/S for up to $2.2 billion, boosting sentiment.&nbsp;The stock is up over 17.5% YTD.Actinium Pharmaceuticals Inc. (600% Jump in Message Volume)Actinium is launching trials for its drug Actimab-A in combination with Merck’s Keytruda and Bristol Myers Squibb’s Opdivo to treat solid tumors. The trials will include head-to-head studies comparing Actimab-A combinations to standalone treatments.&nbsp;The company also entered a research agreement with Memorial Sloan Kettering to expand Actimab-A’s applications.&nbsp;Actinium stock is up over 22% YTD.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A person examines financial data on a screen displaying a graph with upward and downward trends, using a pen to trace the line chart. | Representative Image: Getty Images

Regencell, GlucoTrack, TC Biopharm, AbbVie, Actinium: 5 Health Care Stocks That Lit Up Retail Discussions Last Week

Investors reacted to insider buying, clinical trial updates, and strategic business shifts that happened in the week ended March 21, 2025.

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. It also develops and markets medicines for relapsed or refractory cancer patients. The company was founded in 2000 and is headquartered in New York, NY.

ATNM
Actinium Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Latest ATNM News

ATNMActinium Pharmaceuticals Inc